reference
How drug tests work
A technical primer on lateral-flow immunoassay chemistry, cutoffs, confirmation testing, specimen validity, and the regulatory framework that governs point-of-care drug screening.
·9 min read
Quick answer
Most point-of-care drug tests are lateral-flow competitive-binding immunoassays. A urine sample wicks across a membrane impregnated with drug-specific antibodies and a colored conjugate; if the targeted drug or metabolite is present at or above the device's cutoff, it blocks the conjugate from binding at the test line, producing a positive result. Any presumptive positive should be confirmed at a SAMHSA-certified laboratory by GC/MS or LC-MS/MS before adverse action is taken.
Lateral-flow immunoassay — the chemistry behind the line
Almost every point-of-care urine drug test on the market — including Magenta's CLIA-waived dip cards and cups — is built around the same fundamental design: a lateral-flow competitive-binding immunoassay. The test strip is a narrow strip of nitrocellulose membrane with three functional zones. At the sample-application end, the membrane is impregnated with a colored conjugate: small particles (typically gold or colored latex) bound to a synthetic drug analog. At the test line, the membrane carries immobilized antibodies that bind specifically to the targeted drug or metabolite. At the control line, a second antibody binds the conjugate regardless of drug presence.
When urine wicks up the strip, it carries the colored conjugate with it. If no drug is present in the sample, the conjugate reaches the test line and binds to the immobilized antibodies, producing a visible colored line. That visible test line means negative. If drug is present in the sample at or above the cutoff concentration, free drug molecules occupy the antibody binding sites at the test line before the conjugate arrives — the conjugate cannot bind, and no test line forms. That absent test line means presumptive positive. The control line forms in either case as long as fluid flowed correctly across the strip.
This competitive-binding chemistry is why drug tests "read backwards" relative to many other lateral-flow tests: presence of analyte makes the line disappear, not appear. It also explains why an absent or faded control line invalidates the result entirely — without confirmation that fluid flowed and reagents activated, the test line's appearance or absence carries no meaning. Operators should be trained to recall the specimen rather than report an invalid result.
What cutoffs mean and how they're chosen
A cutoff is the concentration of analyte at which a test transitions from reporting negative to reporting positive. Cutoffs are not arbitrary numbers — they are chosen to balance sensitivity (catching real users) against specificity (not flagging incidental exposure), with reference to the pharmacokinetics of the substance and the operational purpose of the test. SAMHSA publishes the cutoffs that apply to federally regulated workplace urine testing: 50 ng/mL for THC-COOH (15 ng/mL on confirmation), 150 ng/mL for benzoylecgonine (cocaine), 500 ng/mL for amphetamines (250 ng/mL on confirmation), and so on.
Non-federal programs are free to set lower cutoffs when greater sensitivity is operationally important. Substance-use-disorder treatment programs and pain-management clinics often screen THC at 20 ng/mL rather than 50 to better detect continued use during monitoring. Forensic laboratories may use even lower cutoffs. The trade-off is real: a lower cutoff catches more long-tail use but also picks up more passive exposure, including legal hemp-derived CBD products that contain trace THC.
Cutoff levels are characteristic of the specific assay and the matrix. SAMHSA oral-fluid cutoffs are different from urine cutoffs because the relevant analyte and the pharmacokinetic profile differ. Hair testing uses concentration-per-mass-of-hair units (pg/mg) rather than ng/mL. Programs comparing results across matrices should not assume the numerical values are equivalent.
Screening versus confirmation — the two-step process
The industry-standard testing workflow is a two-step process. The initial screen is an immunoassay — either a laboratory analyzer or a point-of-care device — that produces a presumptive negative or presumptive positive result. Immunoassays are designed to be sensitive and inexpensive, which means they will occasionally produce false positives from cross-reacting compounds. SAMHSA-regulated and DOT-regulated programs require that every presumptive positive be confirmed before any adverse action is taken.
Confirmation testing is performed at a SAMHSA-certified laboratory using gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS). These instrumental methods identify the targeted analyte by its specific mass spectrum and retention time, distinguishing it from any cross-reacting compound, and quantify it precisely. Confirmation cutoffs are typically lower than screening cutoffs because the confirmation method is more specific and the regulatory intent is to confirm the exposure flagged by the screen, not to re-screen at the same threshold.
Confirmed laboratory positives in workplace settings are then reviewed by a Medical Review Officer (MRO) — a licensed physician trained in substance-abuse testing — who contacts the donor, evaluates any legitimate medical explanation (most commonly a prescription medication), and reports a verified result to the employer. This two-step (or three-step, counting MRO review) workflow is the procedural backbone of defensible workplace and clinical testing.
| Step | Method | Purpose | Where performed |
|---|---|---|---|
| Screen | Lateral-flow or analyzer immunoassay | Presumptive positive/negative at cutoff | Point of care or laboratory |
| Confirmation | GC/MS or LC-MS/MS | Specific identification and quantification | SAMHSA-certified laboratory |
| MRO review | Physician interview and record review | Identify legitimate medical explanations | Independent MRO |
Specimen validity testing — proving the sample is real
A drug test result is only as good as the specimen behind it. Validity testing is the parallel set of measurements that establishes whether a urine sample is genuine, undiluted, and free of adulterants. The four validity parameters required by SAMHSA's urine guidelines are creatinine concentration, specific gravity, pH, and an oxidant/general-adulterant check. Modern integrated cups and many dip-card formats include validity pads alongside the drug-screening analytes.
Creatinine and specific gravity together identify dilute specimens. A creatinine below 20 mg/dL or specific gravity below 1.003 indicates dilution; if either falls below 2 mg/dL or 1.0010 respectively, SAMHSA classifies the specimen as substituted (not consistent with normal human urine). pH outside the normal physiological range (4.5–9.0) suggests adulteration with a household chemical. Oxidant pads detect oxidizing agents such as nitrite, glutaraldehyde, pyridinium chlorochromate, and other compounds marketed in products that claim to defeat drug tests.
A specimen that fails validity testing is generally treated as a refusal to test under federal rules, which carries consequences equivalent to a confirmed positive. Programs that omit validity testing are leaving a substantial integrity gap in their screening protocol — point-of-care devices with integrated validity pads close that gap with no incremental workflow cost.
Cross-reactivity and false positives, explained
Cross-reactivity refers to an immunoassay's response to compounds other than its intended target. Antibodies bind based on molecular shape, and any compound whose shape resembles the target can produce a signal. The classic examples include pseudoephedrine and certain other over-the-counter sympathomimetics triggering amphetamine assays, poppy-seed products triggering opiate assays, and a small set of antibiotics (most notoriously certain quinolones) showing variable cross-reactivity on older opiate immunoassays.
Every FDA-cleared immunoassay's package insert lists the compounds it has been tested against and the concentrations at which cross-reactivity has been characterized. Cross-reactivity is a known, characterized, manageable property — it is not a defect in the assay. The two-step screening-plus-confirmation workflow exists precisely so that any cross-reactivity-driven false positive is resolved by mass spectrometry before adverse action.
False positives in the strict statistical sense (test reports positive when no targeted analyte is present) are rare on well-designed modern immunoassays at standard cutoffs. False negatives — donor used the drug but the test missed it — are more common in real workplace operations and typically reflect collection-timing issues, cutoff levels too high to catch the exposure, or use of a drug that the panel does not include. The most consequential example is fentanyl: standard opiate immunoassays do not detect it, so a fentanyl user passes a SAMHSA-5 panel by definition.
FDA clearance and CLIA waivers
Two parallel regulatory pathways govern point-of-care drug-test devices in the United States. The Food and Drug Administration (FDA) clears in vitro diagnostic devices through the 510(k) premarket-notification process; FDA clearance establishes that the device is substantially equivalent to a legally marketed predicate and is safe and effective for its intended use. Most point-of-care immunoassay devices on the market — including Magenta's dip cards and cups — are FDA-cleared 510(k) devices.
The Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS), regulate the laboratories and sites that perform testing. CLIA categorizes tests by complexity: waived, moderate, and high. A waived test is one CMS has determined to be simple enough and low-risk enough that it can be performed in a non-laboratory setting (a clinic, an HR office, a treatment program) under a CLIA Certificate of Waiver. Magenta's CLIA-waived devices carry that designation, which is what allows non-laboratory operators to use them.
Operators of waived tests are still required to follow the manufacturer's instructions for use exactly, including specimen handling, read-time windows, and storage. Deviations from the package insert can void the CLIA-waived status of the test event and produce results that are not defensible in any subsequent challenge.
Accuracy terminology — sensitivity, specificity, PPV, and NPV
Sensitivity is the probability that a true positive will test positive; specificity is the probability that a true negative will test negative. These are intrinsic test characteristics that do not depend on the population being tested. Positive predictive value (PPV) and negative predictive value (NPV) are the probabilities that a positive or negative result is truly correct — and these depend heavily on the underlying prevalence of use in the tested population. In a low-prevalence population (random workplace screening), even a high-specificity test will produce a meaningful fraction of false positives by sheer base-rate arithmetic, which is precisely why mass-spectrometry confirmation is required before action.
Key takeaways
- ✓Point-of-care drug tests are lateral-flow competitive-binding immunoassays — the colored test line means negative, an absent test line means presumptive positive.
- ✓An absent control line invalidates the result entirely; the specimen should be recollected rather than reported.
- ✓Cutoffs are calibrated to balance sensitivity against specificity and are matrix-specific; SAMHSA publishes the federally required urine and oral-fluid cutoffs.
- ✓Every presumptive positive should be confirmed at a SAMHSA-certified laboratory by GC/MS or LC-MS/MS before any adverse action.
- ✓Specimen validity testing (creatinine, pH, specific gravity, oxidant panel) is required by federal rules and should accompany every workplace screen.
- ✓Cross-reactivity is a known, characterized property of immunoassays; the two-step screen-plus-confirmation workflow exists to resolve it before action.
- ✓FDA clearance (510(k)) governs the device; CLIA waivers (CMS) govern who is allowed to operate it in a non-laboratory setting.
- ✓Positive predictive value depends on population prevalence — mass-spectrometry confirmation is what makes a positive defensible in low-prevalence screening.
Sources
- SAMHSA·Mandatory Guidelines for Federal Workplace Drug Testing Programs (Urine)
- FDA·510(k) Premarket Notification — In Vitro Diagnostic Devices
- CDC·Clinical Laboratory Improvement Amendments (CLIA) — Test Categorization
- NIDA·Urine Drug Testing — Overview and Interpretation
Information in this article is provided for educational reference and is not medical, legal, or clinical advice. Consult qualified professionals for guidance specific to your program.